Skip to main content
. 2020 Jun 29;15(6):e0231856. doi: 10.1371/journal.pone.0231856

Table 4. Number of days with unscheduled bleeding and/or spotting by treatment period.

Cycle DRSP 4mg (N = 858) DSG 0.075mg (N = 332) Total (N = 1190) Wilcoxon-rank-sum-test p value
Cycles 2–4 N 527 222 749
Mean (SD) 9.6 (11.58) 16.9 (16.93) 11.7 (13.80) <0.0001
Median 5.0 12.0 7.0
Min/ Max 0/66 0/79 0/79
Cycles 5–7 N 423 157 580
Mean (SD) 7.4 (9.53) 10.6 (12.69) 8.3 (10.56) 0.0232
Median 4.0 7.0 4.0
Min/ Max 0/67 0/61 0/67
Cycles 7–9 N 374 137 511
Mean (SD) 7.2 (8.85) 10.8 (13.34) 8.2 (10.35) 0.0277
Median 4.0 7.0 4.0
Min/ Max 0/51 0/83 0/83
Cycles 2–6 N 422 172 594
Mean (SD) 13.7 (15.98) 23.7 (24.69) 16.6 (19.44) <0.0001
Median 7.0 17.0 9.5
Min/ Max 0/89 0/134 0/134
Cycles 2–9 N 305 116 421
Mean (SD) 21.5 (22.86) 34.7 (33.73) 25.1 (26.92) 0.0003
Median 14.0 26.0 16.0
Min/ Max 0/95 0/156 0/156

N: number of patients in specified treatment group; n: number of patients with data available; SD: Standard Deviation